^
    Back
    Association details:
    Biomarker:KRAS G12R
    Cancer:Pancreatic Ductal Adenocarcinoma
    Regimen: (5-fluorouracil + irinotecan + leucovorin calcium + oxaliplatin)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GI 2023
    Title:

    Prognostic indicators of KRAS G12X mutations in pancreatic cancer.

    Published date:
    01/17/2023
    Excerpt:
    The patients with KRAS G12R mutant tumors had significantly longer median real-world overall survival (mRWOS) compared to G12D (452 vs 358 days, HR 0.82, CI 0.74 – 0.9, p < 0.0001). This difference persisted regardless of treatment with FOLFIRINOX or gemcitabine plus nab-paclitaxel....Patients with KRAS G12R variants has improved rwOS compared to G12D irrespective of the chemotherapy regimen administered.
    DOI:
    10.1200/JCO.2023.41.3_suppl.735